A Phase II Trial of Docetaxel, Cetuximab (C225), and Cisplatin Followed by Radiation, Cetuximab, and Cisplatin in Locally Advanced Head and Neck Cancer
This research study involves the use of a combination of two chemotherapies, cisplatin and
docetaxel, which have been known to shrink head and neck cancers and are a commonly used
treatment for this type of cancer. This combination will then be followed by radiation and
more chemotherapy.
The purpose of this study is to see whether this combination of chemotherapy and radiation,
with the addition of Cetuximab, can improve control of disease and collect information on
what side effects this combination therapy may have. In addition, biologic factors (markers)
will be studied that may help to predict and treat head and neck cancer patients in the
future.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the objective response rate with induction with cisplatin/docetaxel/cetuximab in subjects.
10 years
No
Michael Gibson, MD
Principal Investigator
University of Pittsburgh
United States: Food and Drug Administration
05-003
NCT00226239
October 2005
December 2015
Name | Location |
---|---|
University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania 15213 |